Publications by authors named "Moh-Lim Ong"
Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019-2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, 'typical' hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined.
View Article and Find Full Text PDFRationale And Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval. This real-world database study examined outcomes for adult patients switching to ravulizumab from eculizumab and patients treated with individual treatments.
Study Design: A retrospective, observational study using the Clarivate Real World Database.
Article Synopsis
- The study focuses on the diverse phenotypic and genotypic profiles of transthyretin amyloidosis (ATTR amyloidosis) in Western Europe, based on data from the ongoing THAOS survey.
- The research found significant variability in genotypes and phenotypes among 1411 symptomatic subjects from nine countries, highlighting mutations linked to a prevalent cardiac phenotype characterized by specific heart conditions.
- The results indicate that patients with the cardiac phenotype have worse survival rates compared to those with other genotypes or neurologic phenotypes, emphasizing the need for greater awareness of this often underdiagnosed condition.
Unlabelled: Transthyretin amyloidosis (ATTR) is characterized by the deposit of mutant or wild-type transthyretin that forms amyloid fibrils, which are extracellularly deposited within tissues and organs. Clinical manifestations of familial amyloid polyneuropathy vary according to the mutation, age at onset and geographical location. This study aimed to describe baseline disease characteristics of Brazilian patients with transthyretin familial amyloid polyneuropathy (ATTR-FAP) enrolled in the Transthyretin Amyloidosis Outcome Survey (THAOS).
View Article and Find Full Text PDFArticle Synopsis
- Transthyretin amyloidosis (ATTR) often leads to heart issues like conduction disease and restrictive cardiomyopathy, contributing to heart failure; Myocardial Contraction Fraction (MCF) is a measure that may better predict mortality than ejection fraction (EF) in these patients.
- In a study of 530 ATTR patients, those with an MCF below 25% had a significantly higher risk of death (HR 8.5) compared to those with an EF below 50% (HR 2.8), showing MCF's stronger predictive value for survival.
- A predictive model combining MCF with factors like blood pressure, kidney function, heart disease symptoms,
Introduction: The effectiveness of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) was evaluated using data from the Transthyretin Amyloidosis Outcomes Survey (THAOS) registry.
Methods: Subjects receiving tafamidis (n = 252) were compared with untreated subjects in a non-randomized, matched cohort analysis. Subjects were matched with up to four untreated controls by genetic mutation, region of birth, and mean treatment propensity score.
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, progressive, life-threatening, hereditary disorder caused by mutations in the transthyretin gene and characterized by extracellular deposition of transthyretin-derived amyloid fibrils in peripheral and autonomic nerves, heart, and other organs. TTR-FAP is frequently diagnosed late because the disease is difficult to recognize due to phenotypic heterogeneity. Based on published literature and expert opinion, symptom clusters suggesting TTR-FAP are reviewed, and practical guidance to facilitate earlier diagnosis is provided.
View Article and Find Full Text PDFPurpose: To systematically evaluate the safety and efficacy of latanoprost monotherapy for the treatment of patients with angle-closure glaucoma.
Methods: We searched EMBASE, Medline, Cochrane Library, Chinese Journal Full-text Database (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wang Fang using the search terms "latanoprost" (or its commercial name, Xalatan) and "angle-closure glaucoma." Resulting articles were then screened using preset inclusion criteria.
Background: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG).
Methods: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events.
Background: Candidemia is a significant cause of morbidity and mortality in hospitalized patients, particularly in Asia. Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different.
Methods: An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries.
Objectives: To explore by a pooled subanalysis of the Global Better Sex Survey sexual aspirations and unmet needs of men and women from Hong Kong, Indonesia, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand.
Methods: To qualify, respondents must have had sexual intercourse at least once in the past 12 months. Women must have had heterosexual intercourse.